

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 65078

Title: First-line Pazopanib in Patients with Advanced Non-Clear Cell Renal Carcinoma:
an Italian Case Series

Reviewer's code: 05223955

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor, Surgeon, Surgical Oncologist

Reviewer's Country/Territory: Japan

Author's Country/Territory: Italy

Manuscript submission date: 2021-02-27

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-04-07 04:14

Reviewer performed review: 2021-04-07 04:34

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

There is no real clinical hesitation in the Asia-Oceania region to use pazopanib in nccRCC patients, but this difference in perception should be corrected again using the EAU and AUA guideline recommendations as an example. Please revise the text in Introduction section.